All In Biotech

Drug Trial Radar · NCT02759419

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jun 16, 2016

Primary completion

Sep 15, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Conditions

  • Hypertension, Pulmonary

Interventions

  • Adempas (Riociguat, BAY63-2521)Drug

    0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-emergent adverse events (TEAEs) as measure of safety and tolerabilityTime frame: Up to approx. 3 years

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Besançon, France

  • Site not named

    Brest, France

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Lille, France

  • Site not named

    Rouen, France

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, Seoul Teugbyeolsi, South Korea

  • Site not named

    Seoul, Seoul Teugbyeolsi, South Korea

  • Site not named

    Seoul, Seoul Teugbyeolsi, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.